Threshold Pharmaceuticals Presents Interim Data From a Phase 1/2 Clinical Trial of TH-302 At Melanoma Conference
October 08, 2009 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Oct. 8, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated...
Threshold Pharmaceuticals Completes $35 Million Private Equity Financing
October 06, 2009 08:25 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Oct. 6, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced the completion of its previously announced private placement of common stock and...
Threshold Pharmaceuticals Announces Private Equity Financing of $35 Million
September 30, 2009 08:31 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 30, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it has entered into a securities purchase agreement with a select group of...
Threshold Pharmaceuticals Provides Clinical Trial Update From a Complete Phase 1/2 Clinical Trial of TH-302 in Combination With Chemotherapy
September 21, 2009 08:45 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 21, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated...
Threshold Pharmaceuticals Announces a Presentation At the ECCO/ESMO Multidisciplinary Congress
September 18, 2009 08:25 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 18, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation of clinical trial results on its hypoxia-activated prodrug,...
Threshold Pharmaceuticals Reports Second Quarter 2009 Financial Results
August 06, 2009 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 6, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today reported financial results for the second quarter ended June 30, 2009.
The net loss for...
Results From TH-302 Clinical Trials Presented at International Lung Cancer Meeting
August 04, 2009 16:05 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif and SCOTTSDALE, Ariz, Aug. 4, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare today...
Threshold Pharmaceuticals ASCO Webcast Available On Company Website
June 08, 2009 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., June 8, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that a webcast of the Company's ASCO investor presentation is now available on the...
Threshold Pharmaceuticals Presents Encouraging Data From Clinical Trials of TH-302 for Solid Tumors
June 01, 2009 08:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., June 1, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) previously announced on May 30, 2009, clinical trial results related to its clinical stage...
Threshold Pharmaceuticals Presents Encouraging Data From Clinical Trials of TH-302 for Solid Tumors
May 30, 2009 08:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 30, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to its clinical stage hypoxia-activated prodrug,...